Table 2a.
Prevalence of chronic health conditions of survivors of osteosarcoma (OS) (N=117) and community controls (N=272).
| Cardiomyopathy | Hypertension | Myocardial infarction | Hypercholesterolemia | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| Normal | 93 | (79.5) | 270 | (99.3) | <0.001 | 45 | (38.5) | 153 | (56.3) | 0.001 | 108 | (92.3) | 269 | (98.9) | 0.001 | 70 | (59.8) | 191 | (70.2) | 0.045 | ||||
| Grade 1 | 0 | (0) | 0 | (0) | 37 | (31.6) | 79 | (29.0) | 0 | (0) | 2 | (0.7) | 32 | (27.4) | 64 | (23.5) | ||||||||
| Grade 2 | 8 | (6.8) | 1 | (0.3) | 20 | (17.1) | 31 | (11.4) | 1 | (0.9) | 0 | (0) | 14 | (12.0) | 17 | (6.3) | ||||||||
| Grade 3 | 14 | (12.0) | 1 | (0.3) | 15 | (12.8) | 9 | (3.3) | 8 | (6.8) | 1 | (0.4) | 1 | (0.9) | 0 | (0) | ||||||||
| Grade 4 | 2 | (1.7) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||
| Hypertriglyceridemia | Peripheral Motor Neuropathy | Peripheral Sensory Neuropathy | Chronic Kidney Disease | |||||||||||||||||||||
| OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| 88 | (75.2) | 219 | (80.5) | 0.25 | 97 | (82.9) | 272 | (100) | <0.001 | 61 | (52.1) | 237 | (87.1) | <0.001 | 108 | (92.3) | 269 | (98.9) | 0.001 | |||||
| Grade 1 | 21 | (18.0) | 42 | (15.4) | 8 | (6.8) | 0 | (0) | 48 | (41.0) | 30 | (11) | 0 | (0) | 0 | (0) | ||||||||
| Grade 2 | 8 | (6.8) | 10 | (3.7) | 10 | (8.5) | 0 | (0) | 6 | (5.1) | 5 | (1.8) | 7 | (6.0) | 3 | (1.1) | ||||||||
| Grade 3 | 0 | (0) | 1 | (0.3) | 2 | (1.7) | 0 | (0) | 2 | (1.7) | 0 | (0) | 2 | (1.7) | 0 | (0) | ||||||||
| Grade 4 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||
| Decreased Bone Mineral Density | Scoliosis | Prosthetic Malfunction‡ | Sensorineural Hearing Loss | |||||||||||||||||||||
| OS Survivors | Controls† | OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| Normal | 74 | (63.2) | -- | -- | -- | 96 | (82.0) | 271 | (99.6) | <0.001 | 19 | (41.3) | -- | -- | -- | 71 | (60.7) | 264 | (97.1) | <0.001 | ||||
| Grade 1 | 39 | (33.3) | -- | -- | 14 | (12.0) | 1 | (0.4) | 0 | (0) | -- | -- | 7 | (6.0) | 5 | (1.8) | ||||||||
| Grade 2 | 4 | (3.4) | -- | -- | 7 | (6) | 0 | (0) | 1 | (2.2) | -- | -- | 8 | (6.8) | 0 | (0) | ||||||||
| Grade 3 | 0 | (0) | -- | -- | 0 | (0) | 0 | (0) | 26 | (56.5) | -- | -- | 23 | (19.7) | 0 | (0) | ||||||||
| Grade 4 | 0 | (0) | -- | -- | 0 | (0) | 0 | (0) | 0 | (0) | -- | -- | 8 | (6.8) | 3 | (1.1) | ||||||||
| Abnormal FEV1 | Abnormal TLC | Abnormal DLCOcorr | ||||||||||||||||||||||
| OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | |||||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | ||||||||||
| Normal | 89 | (76.1) | 252 | (92.6) | <0.001 | 110 | (94.0) | 265 | (97.4) | 0.14 | 91 | (77.8) | 259 | (95.2) | <0.001 | |||||||||
| Grade 1 | 16 | (13.7) | 12 | (4.4) | 2 | (1.7) | 6 | (2.2) | 0 | (0) | 12 | (4.4) | ||||||||||||
| Grade 2 | 8 | (6.8) | 5 | (1.8) | 2 | (1.7) | 1 | (0.3) | 25 | (21.4) | 1 | (0.3) | ||||||||||||
| Grade 3 | 2 | (1.7) | 3 | (1.1) | 3 | (2.6) | 0 | (0) | 1 | (0.9) | 0 | (0) | ||||||||||||
| Grade 4 | 2 | (1.7) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||||||
| Abnormal Fasting Glucose | Overweight/Obesity | Sex Hormone Insufficiency* | Oligospermia/Azoospermia** | |||||||||||||||||||||
| OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls | OS Survivors | Controls† | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| Normal | 92 | (78.6) | 218 | (80.1) | 0.73 | 44 | (37.6) | 100 | (36.8) | 0.88 | 95 | (92.2) | 232 | (96.7) | 0.093 | 20 | (54.1) | -- | -- | -- | ||||
| Grade 1 | 22 | (18.8) | 43 | (15.8) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | -- | -- | ||||||||
| Grade 2 | 2 | (1.7) | 10 | (3.7) | 36 | (30.8) | 69 | (25.4) | 4 | (3.9) | 0 | (0) | 8 | (21.6) | -- | -- | ||||||||
| Grade 3 | 1 | (0.9) | 1 | (0.4) | 31 | (26.5) | 78 | (28.7) | 4 | (3.9) | 8 | (3.3) | 9 | (24.3) | -- | -- | ||||||||
| Grade 4 | 0 | (0) | 0 | (0) | 6 | (5.1) | 25 | (9.2) | 0 | (0) | 0 | (0) | 0 | (0) | -- | -- | ||||||||
FEV1: forced expiratory volume in one second; TLC: total lung capacity; DLCOcorr: diffusion capacity of lungs for carbon monoxide corrected for hemoglobin
†
Not assessed among controls
‡
Assessed among survivors with primary limb-sparing surgery (n=46)
*
Assessed among evaluable survivors (n=103) and controls (n=240); women above age of 40 years or actively receiving hormonal therapy were considered inevaluable
**
Assessed among male survivors who consented to semen analysis (n=37)